Abstract:Rationale: T-cell-redirecting bispecific antibodies (bsAbs) and trispecific antibodies (tsAbs) designed to recognize different epitopes or antigens have emerged as promising cancer therapies. Current approaches are all designed to include another antibody specific to the site of the primary antibody, and the molecular structures are generally established. However, the dimensions of target molecule and epitope location play a key role in the efficiency of the immunological synapse (IS) formation and subsequent T-cell-redirecting activities, therefore the connection flexibility of these antibodies determines the geometries of different formats of these molecules and will have a major impact on the efficacy. Methods: We describe a novel recombination strategy using various linker designs to site-specifically fuse anti-Her2 (2Rs15) or anti-VEGFR2 (3VGR19) nanobodies to different positions of the anti-CD3 antibody fragment (Fab, SP34). Based on the comparison among the various antigen-specific bsAbs, we could determine the desired fusion site of each nanobody to SP34, and further ensure the optimal structure of tsAbs with synergistic dual-antigen enhanced T-cell-redirecting activities. Results: This approach allows precise control of the formation of IS between Her2- and/or VEGFR2-expressing cancer cells and T cells, to obtain the optimal structure of the Her2/VEGFR2/CD3 tsAb without the need to map antibody-binding epitopes. Optimization of Her2/VEGFR2/CD3 tsAb results in enhanced T-cell-redirecting in vitro and in vivo antitumor efficacy compared with the corresponding bsAbs alone or in combination, and the potency to overcome tumor relapse due to antigen escape or resistance to Herceptin and Cyramza therapy. Conclusion: The novel design strategy for developing tsAbs using a site-specific recombination approach represents a promising platform for immuno-oncology and in applications other than cancer therapy.

Trispecific Antibodies for Cancer Immunotherapy

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

Current landscape and future directions of bispecific antibodies in cancer immunotherapy

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Immunotherapeutic progress and application of bispecific antibody in cancer

The Application of the Drugs of Bispecific Antibodies in Anti-Tumor Therapy

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy

A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy

Therapeutic Bispecific Antibodies Against Intracellular Tumor Antigens

Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL

Unlocking the potential of bispecific ADCs for targeted cancer therapy

Recent advances and challenges of bispecific antibodies in solid tumors

Bispecific Antibodies: From Research to Clinical Application

A trispecific T cell engager CD19xCD3xCD28 induces potent tumor-directed T cell activation and antitumor activity by simultaneously engagement of TCR and a co-stimulatory receptor CD28

The present and future of bispecific antibodies for cancer therapy

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials